TL;DR: Even a globally reputable company using trusted partners can stumble into serious compliance breaches online. All pharma professionals should be proactive, transparent, and vigilant—especially with third-party digital campaigns. The future of ethical pharmaceutical advertising depends on it. For many…
Ever wondered how something as innocent as a LinkedIn ‘like’ could pull an entire pharma company into PMCPA hot water? I once underestimated how quickly a digital echo can travel, but the Moderna mRESVIA PMCPA case showed the true power…
What 214 Social Media cases taught me about compliance risk I’ve just finished reviewing 214 PMCPA cases where social media played a role. The pattern is undeniable: LinkedIn and other platforms are now a leading source of ABPI Code breaches.…
Let me take you behind the scenes of a Jazz Pharmaceuticals case that could have happened to any of us. In my early years as a final signatory I found myself agonising over whether mentioning a drug’s brand name too…
Every congress season, the influx of last-minute speaker decks exposes a familiar vulnerability in pharmaceutical communications. Speed, while necessary, brings competitor risk sharply into focus. Substantiation lapses, inconsistencies, and unsupported claims can inadvertently invite challenge under the 2024 ABPI Code…
Every spring and summer, the congress season breathes energy into the pharmaceutical world—a moment brimming with anticipation for product progress, emerging data, and unbiased scientific interchange. Yet at every congress, a quiet tension surfaces: how do industry professionals champion transparency…
